

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cushing syndrome | D003480 | EFO_0003099 | E24 | 2 | 2 | 2 | — | — | 6 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 2 | — | — | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | 2 | — | — | 4 |
| Ectopic acth syndrome | D000182 | EFO_1001256 | E24.3 | 1 | 1 | 2 | — | — | 4 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | 1 | — | — | 4 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | 1 | 2 | 1 | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 2 | 1 | — | — | 3 |
| Fallopian tube neoplasms | D005185 | — | — | — | 2 | 1 | — | — | 3 |
| Peritoneal neoplasms | D010534 | — | — | — | 1 | 1 | — | — | 2 |
| Pancreatic ductal carcinoma | D021441 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal cortex neoplasms | D000306 | — | C74.0 | 1 | 1 | — | — | — | 2 |
| Adrenocortical carcinoma | D018268 | — | — | 1 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | — | 1 | — | — | — | 1 |
| Neoplasms by site | D009371 | — | — | — | 1 | — | — | — | 1 |
| Ovarian diseases | D010049 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 1 | — | — | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | — | — | — | — | 1 |
| Hyperglycemia | D006943 | — | R73.9 | 1 | — | — | — | — | 1 |
| Adrenal gland diseases | D000307 | — | E27.9 | 1 | — | — | — | — | 1 |
| Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | 1 | — | — | — | — | 1 |
| Pathologic processes | D010335 | — | — | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Food-drug interactions | D018565 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Drug common name | Relacorilant |
| INN | relacorilant |
| Description | Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.
|
| Classification | Small molecule |
| Drug class | glucocorticoid receptor antagonists (not glucocorticoids) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1 |
| PDB | — |
| CAS-ID | 1496510-51-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4068611 |
| ChEBI ID | — |
| PubChem CID | 73051463 |
| DrugBank | — |
| UNII ID | 2158753C7E (ChemIDplus, GSRS) |
